

This is a repository copy of Topical 11β -Hydroxysteroid Dehydrogenase Type 1 Inhibition Corrects Cutaneous Features of Systemic Glucocorticoid Excess in Female Mice.

White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk/123094/

Version: Accepted Version

Article:

Tiganescu, A orcid.org/0000-0003-3688-2204, Hupe, M, Uchida, Y et al. (3 more authors) (2018) Topical 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibition Corrects Cutaneous Features of Systemic Glucocorticoid Excess in Female Mice. Endocrinology, 159 (1). pp. 547-556. ISSN 0013-7227

https://doi.org/10.1210/en.2017-00607

© 2017 Endocrine Society. This is a pre-copyedited, author-produced PDF of an article accepted for publication in © 2017 Endocrine Society following peer review. The version of record, Ana Tiganescu, Melanie Hupe, Yoshikazu Uchida, Theadora Mauro, Peter M Elias, Walter M Holleran; Topical 11β-hydroxysteroid dehydrogenase type 1 inhibition corrects cutaneous features of systemic glucocorticoid excess in female mice, Endocrinology, is available online at: https://doi.org/10.1210/en.2017-00607.


Reuse

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

Takedown


If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.







Supplemental Figure 1. 11β-HSD1 activity in control mice 11β -HSD1 enzyme activity increased during healing and was inhibited by topical CBX (n=4-12, two-way ANOVA). Multiple comparisons: * = vs. baseline (day 0) in each treatment group (Dunnet's test), # = vs. VEH at each time-point (Sidak's test). Significance: * = p<0.05, ** = p<0.01, *** = p<0.001

Supplemental Figure 2. PCNA staining A) Representative PCNA immunostaining (n=4) and **B)** PCNA immunostaining quantification showing a trend towards decreased keratinocyte proliferation in CORT mice and improvement following 7 days topical CBX treatment (n=4, one-way ANOVA). Scale bar 50μm.




Supplemental Figure 3. Skin thickness in control mice A) Representative H+E staining following 7 days topical CBX treatment (n=4), B) Quantification of epidermal thickness (n=4, Student's t-test), C) Quantification of keratinocyte density (n=4, Student's t-test) and D) Quantification of dermal area (n=4, Student's t-test). Scale bar 50μm.





Supplemental Figure 4. Epidermal barrier function in control mice A) Baseline trans-epidermal water loss (TEWL) following 7 days topical CBX treatment (n=12, Student's t-test), B) Barrier integrity (n=12, Student's t-test) and C) Barrier recovery relative to baseline TEWL (n=12, two-way ANOVA). Multiple comparisons: *= vs. 2 hour time-point in each treatment group (Dunnet's test), #= vs. VEH at each time-point (Sidak's test). Significance: *= p<0.05, **= p<0.01, ***= p<0.001



Supplemental Figure 5. Wound healing in control mice A) Representative wound appearance at day 9 (n=8) and **B)** Quantification of wound areas following topical CBX treatment (n=8-24, two-way ANOVA). Scale bar 12mm. Multiple comparisons for B: * = vs. day 4 in each treatment group (Dunnet's test). Significance: * = p<0.05, *** = p<0.001